Form 4: Achieve Life Sciences Executive Chairman Richard Stewart Increases Stake in Company

Richard Stewart, Executive Chairman of Achieve Life Sciences, purchased 10,000 shares of common stock and warrants in a registered direct offering.

Summary

• On March 4, 2024, Richard Stewart, the Executive Chairman of Achieve Life Sciences, acquired 10,000 shares of common stock at a price of $4.585 per share.
• The purchase was part of a registered direct offering (RDO) under a Securities Purchase Agreement (SPA) dated February 28, 2024.
• Stewart also acquired warrants to purchase 10,000 common shares at an exercise price of $4.906.
• Following the transaction, Stewart directly owns 38,501 shares of Achieve Life Sciences.
• The warrants are exercisable immediately and expire either three and one-half years from issuance or 30 days after Achieve Life Sciences publicly discloses FDA acceptance of an NDA for cytisinicline.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the insider buying, which suggests confidence in the company's prospects. However, the transaction is part of a capital raise, which could also indicate a need for funds.

Positives

• The Executive Chairman's purchase of shares signals confidence in the company's future prospects.
• The registered direct offering provides Achieve Life Sciences with additional capital.
• The immediate exercisability of the warrants could provide further capital to the company if exercised.

Risks

• The warrants' expiration being tied to FDA acceptance of an NDA for cytisinicline introduces regulatory risk.
• The value of the warrants is dependent on the share price exceeding the exercise price of $4.906.

Future Outlook

The warrants' exercisability is linked to the FDA's review of cytisinicline, suggesting the company anticipates submitting an NDA and receiving a Day 74 Letter or equivalent correspondence.

Industry Context

Insider buying is often seen as a positive sign, indicating that company leadership believes in the future success of the company. This is especially relevant in the biotech industry, where regulatory approvals and clinical trial outcomes can significantly impact stock prices.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech companies is difficult without knowing the specific context of Achieve Life Sciences' financial situation and clinical trial progress.
• However, generally, insider purchases are viewed favorably by the market, especially when the purchase is of a significant amount relative to the insider's existing holdings.

Stakeholder Impact

• Shareholders may view the insider buying positively.
• The capital raise could dilute existing shareholders' ownership.

Next Steps

• Achieve Life Sciences will likely continue to pursue regulatory approval for cytisinicline.
• The company may seek additional funding in the future.

Key Dates